Physical, Emotional, and Stress-Related Dynamics over Six Months in Newly Diagnosed Epithelial Ovarian Cancer Survivors.

Epithelial ovarian cancer (EOC) remains the deadliest gynecologic malignancy, yet the psychosocial dynamics of early survivorship are inadequately described. We prospectively quantified six-month trajectories in the quality of life in a consecutive cohort of 88 women newly diagnosed with EOC and explored clinical moderators of change. Eighty-eight consecutive patients (mean age 59.1 ± 10.7 years) completed the SF-36, WHOQOL-BREF, EORTC QLQ-C30, and 10-item Perceived Stress Scale (PSS-10) at baseline (pre-therapy) and six months after cytoreductive surgery ± platinum-based chemotherapy. Stage (FIGO I-II vs. III-IV) and treatment pathway (primary debulking surgery, neoadjuvant chemotherapy plus interval debulking, chemotherapy only) data were recorded. Global QoL improved significantly (EORTC Global Health +5.9 ± 7.7 points; < 0.001) while perceived stress declined (ΔPSS -3.6 ± 5.1; < 0.001). SF-36 Physical Functioning rose 4.7 ± 7.9 points ( < 0.001) and Mental Health 4.4 ± 7.9 points ( = 0.004). The WHOQOL Physical and Psychological domains gained 4.7 ± 7.1 and 4.3 ± 7.4 points, respectively (both < 0.01). Advanced-stage patients experienced larger stress reductions than early-stage patients (-4.1 ± 2.7 vs. -2.9 ± 2.2; = 0.028) but comparable QoL gains. Greater stress relief correlated with greater mental-health improvement (r = -0.51) and global-health gains (r = -0.45) (all < 0.001). Treatment pathway did not significantly influence trajectories. Early survivorship after first-line ovarian-cancer therapy was characterized by the clinically meaningful recovery of physical and emotional functioning together with the moderate alleviation of perceived stress. Improvements were observed irrespective of stage and treatment strategy, suggesting that contemporary multimodal regimens do not inevitably compromise patient-reported outcomes. Our estimates provide preliminary effect sizes that should be validated in multi-center cohorts with longer follow-up.